company background image
IMPL.Q logo

IPI Legacy Liquidation Co OTCPK:IMPL.Q Stock Report

Last Price

US$0.015

Market Cap

US$358.5k

7D

-23.9%

1Y

-98.9%

Updated

08 Apr, 2024

Data

Company Financials

IPI Legacy Liquidation Co

OTCPK:IMPL.Q Stock Report

Market Cap: US$358.5k

IMPL.Q Stock Overview

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. More details

IMPL.Q fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

IPI Legacy Liquidation Co Competitors

Price History & Performance

Summary of all time highs, changes and price drops for IPI Legacy Liquidation Co
Historical stock prices
Current Share PriceUS$0.015
52 Week HighUS$2.87
52 Week LowUS$0.007
Beta0.38
11 Month Change97.37%
3 Month Change-86.49%
1 Year Change-98.87%
33 Year Changen/a
5 Year Changen/a
Change since IPO-99.90%

Recent News & Updates

Recent updates

Investors Still Aren't Entirely Convinced By Impel Pharmaceuticals Inc.'s (NASDAQ:IMPL) Revenues Despite 50% Price Jump

Apr 17
Investors Still Aren't Entirely Convinced By Impel Pharmaceuticals Inc.'s (NASDAQ:IMPL) Revenues Despite 50% Price Jump

The Impel Pharmaceuticals Inc. (NASDAQ:IMPL) Full-Year Results Are Out And Analysts Have Published New Forecasts

Mar 30
The Impel Pharmaceuticals Inc. (NASDAQ:IMPL) Full-Year Results Are Out And Analysts Have Published New Forecasts

Impel Pharmaceuticals Inc. (NASDAQ:IMPL) Analysts Just Slashed This Year's Revenue Estimates By 12%

Mar 26
Impel Pharmaceuticals Inc. (NASDAQ:IMPL) Analysts Just Slashed This Year's Revenue Estimates By 12%

Impel NeuroPharma GAAP EPS of -$1.09 misses by $0.04, revenue of $2.8M misses by $1.04M

Aug 15

Impel stock rises as dosing begins in mid-stage trial of INP105 for agitation in autistic people

Jul 19

Impel Pharmaceuticals: Under The Radar Despite Upside Potential

Jun 28

Impel NeuroPharma reports Q1 results

Jun 07

Shareholder Returns

IMPL.QUS BiotechsUS Market
7D-23.9%-7.5%-1.2%
1Y-98.9%14.1%30.4%

Return vs Industry: IMPL.Q underperformed the US Biotechs industry which returned 3.9% over the past year.

Return vs Market: IMPL.Q underperformed the US Market which returned 25.9% over the past year.

Price Volatility

Is IMPL.Q's price volatile compared to industry and market?
IMPL.Q volatility
IMPL.Q Average Weekly Movement97.8%
Biotechs Industry Average Movement9.7%
Market Average Movement6.2%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.1%

Stable Share Price: IMPL.Q's share price has been volatile over the past 3 months.

Volatility Over Time: IMPL.Q's weekly volatility has increased from 78% to 98% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2008160n/aimpelpharma.com

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022.

IPI Legacy Liquidation Co Fundamentals Summary

How do IPI Legacy Liquidation Co's earnings and revenue compare to its market cap?
IMPL.Q fundamental statistics
Market capUS$358.50k
Earnings (TTM)-US$74.28m
Revenue (TTM)US$20.99m

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IMPL.Q income statement (TTM)
RevenueUS$20.99m
Cost of RevenueUS$9.95m
Gross ProfitUS$11.04m
Other ExpensesUS$85.31m
Earnings-US$74.28m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-3.11
Gross Margin52.58%
Net Profit Margin-353.93%
Debt/Equity Ratio-120.8%

How did IMPL.Q perform over the long term?

See historical performance and comparison